Skip to content
Navigate to homepage - Cerba Research
Resource Library

Poster – Immune Cell Checkpoint Profiling Of Solid Tumors By Multiplex Immunofluorescence

Immune checkpoint proteins are important regulators in self-tolerance but also allow cancer cells to evade immune destruction. Checkpoint inhibitor (CKI) blockade therapies can help restore antitumoral immunity. Combination blockade has demonstrated the potential to result in greater tumor growth inhibition than monotherapies in preclinical studies.

Multiplex immunofluorescence offers a technical advantage by allowing for the detection of co-expression and spatial organization of multiple targets within a preserved tissue architecture on a single slide. We have developed the HISTOPROFILE®-CKI multiplex immunohistochemistry panel to offer personalized immune cell checkpoint profiling.

Reach out to our experts and discover how we can help you advance your clinical trials

Resource Library

Poster – Assessing Clinical Response In Multiple Myeloma (MM) Patients Treated With Monoclonal Antibodies (Mabs): Validation Of A Daratumumab IFE Reflect Assay (DIRA) To Distinguish Malignant M-Protein From Therapeutic Antibody

Reach out to our experts and discover how we can help advance your clinical trial

Resource Library

Fact Sheet – Autoimmune Diseases Clinical Trials- Enhance Your Success In Tackling Autoimmune Diseases

Discover our expertise in the field of Auto Immune diseases.

Investigations into autoimmunity benefit from a multifaceted approach.  

Genetic Testing/NGS

Along with infections and other exposures, genes play a significant role in disease development. Read more

Diagnosis & development

Tissue diagnosis and routine testing register pathology and the course of the disease

Immune monitoring

Gauge response to treatment by following up on the status of immune cells via flow cytometry

Biomarker Testing

Develop and follow serum markers for both diagnosis and prognosis of autoimmune diseases Read more

Reach out to our experts and discover how we can help you advance your clinical trial

Resource Library

Fact Sheet – NASH Clinical Trials – Supporting The Biggest Phase 3 Study In NASH

In a meta-analysis of several studies using various methodologies, worldwide prevalence of NAFLD (Non-alcoholic fatty liver disease) is 25.2% and 6.45% for NASH (Non-Alcoholic SteatoHepatitis). NASH prevalence is expected to increase by 63% between 2015 and 2030, yet the condition is still poorly understood and there is no known treatment. The need for therapeutic agents is urgent.

At Cerba Research, we are committed to improving the diagnosis and treatment for NASH. In 2016, after we successfully supported their Phase II NASH study, a midsize biotech engaged our services for Phase III. Gratified to have gained their trust and eager to continue our productive collaboration with this meticulous client, we rolled up our sleeves and took on the challenge of supporting the largest NASH Phase III study to date.

Discover how Cerba Research was able to support one of the biggest Phase 3 studies in NASH

Reach out to our experts and discover how we can help you advance your clinical trial

Resource Library

Case Study – Phase 3 Clinical Trial On The Efficacy And Safety Of A New Therapy In The Treatment Of Uncomplicated Influenza

Cerba Research performed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a new therapy in the treatment of uncomplicated influenza.

Testing algorithms were complex as multiple PCR results had to be obtained from each sample, with only a single freeze-thaw cycle. Shipping the virology samples was also a challenge since maximum effort should be made to ship samples on the day, alternatively, they would be stored and shipped refrigerated within 48 hours, or on dry ice later.

discover how our experts succeeded

Reach out to our experts and discover how we can help you advance your clinical trial